Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.56 |
| ▸ | LIPC | P11150 | 1/20 | 0.56 |
| ▸ | LIPE | Q05469 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 4/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046524 | 0.89 | MGLL (0.53) | LPLLIPCLIPEMGLLFAAH | |
| SCHEMBL6603090 | 0.74 | LPL (0.60) | LPLLIPCLIPEMGLLFAAH | |
| SCHEMBL6602134 | 0.73 | LPL (0.48) | LPLLIPCLIPEMGLLFAAH | |
| SCHEMBL11620781 | 0.73 | FAAH (0.78) | LPLLIPCLIPEMGLLFAAH | |
| SCHEMBL6603718 | 0.72 | LPL (0.69) | LPLLIPCLIPEMGLLFAAH | |
| SCHEMBL6600998 | 0.71 | LPL (0.55) | LPLLIPCLIPEMGLLFAAH | |
| SCHEMBL6600164 | 0.71 | FAAH (0.56) | LPLLIPCLIPEMGLLFAAH | |
| SCHEMBL6551854 | 0.71 | FAAH (0.74) | LPLLIPCLIPEMGLLFAAH | |
| SCHEMBL6603509 | 0.71 | LPL (0.56) | LPLLIPCLIPEMGLLFAAH | |
| SCHEMBL30418675 | 0.71 | RAB9A (0.77) | NPC1RAB9AFLT3SMN1; SMN2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6369088-B2 | ANTIDIABETIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | CNR1, PTGER1, CNR2 | LPL 1845/4885LIPC 554/4885LIPE 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.